Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 24, 2021
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
[ Thu, Jun 24th 2021
] - WOPRAI
Wed, June 23, 2021
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
[ Wed, Jun 23rd 2021
] - WOPRAI
Robyn Karnauskas Maintained (BTAI) at Strong Buy with Decreased Target to $125 on, Jun 23rd, 2021
Robyn Karnauskas of Truist Securities, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $128 to $125 on, Jun 23rd, 2021.
Robyn has made no other calls on BTAI in the last 4 months.
There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Robyn's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Robyn
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $176 on, Tuesday, June 1st, 2021
- Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
